不同剂量瑞舒伐他汀对急性冠脉综合征患者心功能和炎症因子的影响(1)
摘要：目的 探討不同剂量瑞舒伐他汀对急性冠脉综合征(ACS)患者心功能和炎症因子的影响。方法 选择心内科收治的126例诊断为ACS患者，随机分为观察组和对照组，各63例。对照组在常规诊疗基础上给予常规剂量的瑞舒伐他汀进行治疗，观察组在常规院内诊疗基础上应用大剂量瑞舒伐他汀进行治疗，对比两组治疗后心功能及炎症因子变化情况及治疗安全性。结果 治疗后观察组心功能分级中Ⅰ级、Ⅱ级患者数分别为15例和32例，优于治疗前的0例和24例以及对照组的10例和27例，差异有统计学意义(P<0.05);对照组治疗后心功能分级也得到了改善，与治疗前比较，差异有统计学意义(P<0.05)。两组治疗后IL-6、TNF-ɑ及hs-CRP水平均低于治疗前，差异有统计学意义(P<0.05)，但观察组各指标下降程度更为明显，差异有统计学意义(P<0.05)。两组不良反应发生率比较，差异无统计学意义(P>0.05)。结论 大剂量应用瑞舒伐他汀可在一定程度上改善患者心功能，降低患者血清炎性因子水平，且临床应用安全性较高。
关键词：急性冠脉综合征;瑞舒伐他汀;心功能;炎症因子
, 百拇医药
中图分类号：R541.4 文献标识码：A DOI：10.3969/j.issn.1006-1959.2019.01.046
文章编号：1006-1959(2019)01-0148-03
Effects of Different Doses of Rosuvastatin on Cardiac Function and Inflammatory Factors in Patients with Acute Coronary Syndrome
ZHAO Dian-ru1，YAN Jing-rui2
(1.Department of Cardiovascular Internal Medicine，Subject Three，People's Hospital of Cangzhou City，Cangzhou 061000，Hebei，China;
, 百拇医药
2.Department of Geriatrics，Cangzhou Central Hospital，Cangzhou 061000，Hebei，China)
Abstract：Objective To investigate the effects of different doses of rosuvastatin on cardiac function and inflammatory factors in patients with acute coronary syndrome (ACS). Methods A total of 126 patients with ACS who underwent cardiology were enrolled in the study. They were randomly divided into observation group and control group， with 63 cases in each group. On the basis of routine diagnosis and treatment， the control group received conventional dose of rosuvastatin for treatment. The observation group was treated in routine hospital. Based on the application of high-dose rosuvastatin， the changes of cardiac function and inflammatory factors were compared between the two groups. The safety of the two groups was observed. Results After treatment， the number of grade I and grade II patients in the observation group was 15 and 32 respectively， which was better than 0 and 24 before treatment and 10 and 27 in the control group， the difference was statistically significant (P<0.05); the cardiac function grading was also improved after treatment in the control group，the difference was statistically significant (P<0.05). The levels of IL-6， TNF-ɑ and hs-CRP in the two groups were lower than those before treatment，the difference was statistically significant (P<0.05)， but the degree of decline in the observation group was more obvious，the difference was statistically significant (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion High-dose rosuvastatin can improve the heart function of patients to a certain extent， reduce the level of serum inflammatory factors in patients， and the safety of clinical application is high., 百拇医药(赵殿儒 祁景蕊)
关键词：急性冠脉综合征;瑞舒伐他汀;心功能;炎症因子
, 百拇医药
中图分类号：R541.4 文献标识码：A DOI：10.3969/j.issn.1006-1959.2019.01.046
文章编号：1006-1959(2019)01-0148-03
Effects of Different Doses of Rosuvastatin on Cardiac Function and Inflammatory Factors in Patients with Acute Coronary Syndrome
ZHAO Dian-ru1，YAN Jing-rui2
(1.Department of Cardiovascular Internal Medicine，Subject Three，People's Hospital of Cangzhou City，Cangzhou 061000，Hebei，China;
, 百拇医药
2.Department of Geriatrics，Cangzhou Central Hospital，Cangzhou 061000，Hebei，China)
Abstract：Objective To investigate the effects of different doses of rosuvastatin on cardiac function and inflammatory factors in patients with acute coronary syndrome (ACS). Methods A total of 126 patients with ACS who underwent cardiology were enrolled in the study. They were randomly divided into observation group and control group， with 63 cases in each group. On the basis of routine diagnosis and treatment， the control group received conventional dose of rosuvastatin for treatment. The observation group was treated in routine hospital. Based on the application of high-dose rosuvastatin， the changes of cardiac function and inflammatory factors were compared between the two groups. The safety of the two groups was observed. Results After treatment， the number of grade I and grade II patients in the observation group was 15 and 32 respectively， which was better than 0 and 24 before treatment and 10 and 27 in the control group， the difference was statistically significant (P<0.05); the cardiac function grading was also improved after treatment in the control group，the difference was statistically significant (P<0.05). The levels of IL-6， TNF-ɑ and hs-CRP in the two groups were lower than those before treatment，the difference was statistically significant (P<0.05)， but the degree of decline in the observation group was more obvious，the difference was statistically significant (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion High-dose rosuvastatin can improve the heart function of patients to a certain extent， reduce the level of serum inflammatory factors in patients， and the safety of clinical application is high., 百拇医药(赵殿儒 祁景蕊)